check_circleStudy Completed

Cystic Fibrosis

Bayer Identifier:

Trial_0696

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available
Pilot study to compare acarbose (BAY g 5421) with placebo in respect of efficacy and tolerability in patients with cystic fibrosis and pathological glucose tolerance

Trial purpose

Please see attached Study Results Summary below.

Key Participants Requirements

Sex

Both

Age

7 - 25 Years
  • -

  • -

Trial summary

Enrollment Goal
12
Trial Dates
November 1993 - September 1995
Phase
Phase 3
Could I Receive a placebo
N/A
Products
Acarbose (Precose/Glucobay, BAYG5421)
Accepts Healthy Volunteer
N/A

Trial design

Double-blind, cross-over clinical study at a single centre to compare acarbose (BAY g 5421) with placebo in respect of efficacy and tolerability in patients with cystic fibrosis and pathological glucose tolerance (pilot study).
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to marketed products.